This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CNCE Concert Pharmaceuticals (CNCE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Concert Pharmaceuticals Stock (NASDAQ:CNCE) 30 days 90 days 365 days Advanced Chart Get CNCE alerts:Sign Up Key Stats Today's Range$8.37▼$8.3750-Day Range$8.33▼$8.4052-Week Range$2.66▼$8.55VolumeN/AAverage Volume2.97 million shsMarket Capitalization$401.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA. Read More Receive CNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNCE Stock News HeadlinesMagnum Wrestling event in Ralston will benefit pediatric cancer organizationSeptember 27, 2024 | omaha.comOStar-Studded Rock4EB! Concert Raises Over $1 Million for 'Butterfly' Skin Disease Epidermolysis BullosaSeptember 23, 2024 | nz.news.yahoo.comBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.August 28 at 2:00 AM | Banyan Hill Publishing (Ad)Man who sold fentanyl-laced pill liable for $5.8 million in death of young female customerSeptember 20, 2024 | msn.comJaney Godley cancels tour and stops work ‘for the foreseeable future’September 18, 2024 | msn.comJane's Addiction cancels tour in the wake of an onstage fightSeptember 16, 2024 | msn.comHair loss, nosebleeds, and a Taylor Swift concert: How I coped with chemoSeptember 14, 2024 | msn.comBreast cancer drug could help prolong survival for children with brain tumors, study findsSeptember 6, 2024 | msn.comSee More Headlines CNCE Stock Analysis - Frequently Asked Questions How were Concert Pharmaceuticals' earnings last quarter? Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) released its earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.03. The biotechnology company had revenue of $0.54 million for the quarter, compared to analysts' expectations of $0.25 million. What other stocks do shareholders of Concert Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Concert Pharmaceuticals investors own include Intel (INTC), Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Global Blood Therapeutics (GBT), Micron Technology (MU), Pfizer (PFE) and NVIDIA (NVDA). Company Calendar Last Earnings11/09/2021Today8/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CNCE CIK1367920 Webwww.concertpharma.com Phone(781) 860-0045Fax302-636-5454Employees64Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$80.05 million Net MarginsN/A Pretax Margin-300,735.69% Return on Equity-109.43% Return on Assets-76.65% Debt Debt-to-Equity RatioN/A Current Ratio9.03 Quick Ratio9.03 Sales & Book Value Annual Sales$32.58 million Price / Sales12.32 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book2.58Miscellaneous Outstanding Shares47,940,000Free Float42,507,000Market Cap$401.26 million OptionableOptionable Beta0.52 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:CNCE) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Concert Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Concert Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access